The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

VIVUS Inc

Nasdaq: VVUS
Last

(U.S.) $1.15

Today's change+0.02 +1.77%
Updated June 22 2:24 PM EDT. Delayed by at least 15 minutes.
 

VIVUS Inc

Nasdaq: VVUS
Last

(U.S.) $1.15

Today's change+0.02 +1.77%
Updated June 22 2:24 PM EDT. Delayed by at least 15 minutes.

VIVUS Inc crosses above 200-day moving average

VIVUS Inc is up sharply today, rallying (U.S.)$0.02 or 1.77% to (U.S.)$1.15 and crossing above its 200-day moving average. Shares have lost 1.71% over the last five days, but are unchanged over the last year to date. This security has underperformed the S&P 500 by 12.44% during the last year.

Key company metrics

  • Open(U.S.) $1.13
  • Previous close(U.S.) $1.13
  • High(U.S.) $1.15
  • Low(U.S.) $1.11
  • Bid / Ask(U.S.) $1.14 / (U.S.) $1.15
  • YTD % change+0.00000%
  • Volume845,402
  • Average volume (10-day)857,214
  • Average volume (1-month)898,545
  • Average volume (3-month)751,176
  • 52-week range(U.S.) $0.93 to (U.S.) $1.47
  • Beta0.85
  • Trailing P/E3.59×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.32
Updated June 22 2:24 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+25.71%

Based on its net profit margin of 25.71%, VIVUS Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.69%Sector:HealthcareIndustry:Biotechnology

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue27821314
Total other revenue--------
Total revenue27821314
Gross profit21801111
Total cost of revenue6223
Total operating expense20171417
Selling / general / administrative11131014
Research & development2221
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--0--0
Other operating expenses, total--------
Operating income765-1-4
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-157-9-11
Income after tax-157-9-11
Income tax, total0000
Net income-157-9-11
Total adjustments to net income--------
Net income before extra. items-157-9-11
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-157-9-11
Inc. avail. to common incl. extra. items-157-9-11
Diluted net income-157-9-11
Dilution adjustment--0--0
Diluted weighted average shares105107104104
Diluted EPS excluding extraordinary itemsvalue per share-0.010.53-0.09-0.11
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.010.53-0.09-0.11